Compared to anti-EpCAM antibody, anti-G250 antibody shows a higher sensitivity for RCC-CTC, and there is a higher staining affinity for these specific cell lines than in other urological cancers (such as those of bladder and prostate). Here, EPCAM is linked to renal cell carcinoma.